Last reviewed · How we verify
Fluconazol
At a glance
| Generic name | Fluconazol |
|---|---|
| Sponsor | Azienda Sanitaria-Universitaria Integrata di Udine |
| Target | Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Candidal Urinary Tract Infection
- Candidal septicemia
- Candidal vulvovaginitis
- Candidemia
- Candidiasis of mouth
- Candidiasis of the esophagus
- Cryptococcal meningitis
- Disseminated candidiasis
- Mucocutaneous candidiasis
- Oropharyngeal Candidiasis
- Prevention of Disseminated Candidiasis
Common side effects
- Headache
- Nausea
- Abdominal pain
- Diarrhea
- Dyspepsia
- Dizziness
- Taste perversion
- Skin rash
- Vomiting
Serious adverse events
- Fulminant hepatic failure
- Clinical hepatitis
- Cholestasis
- Anaphylactic reaction
- Angioedema
- Serum transaminase elevations >8x upper limit of normal
Key clinical trials
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) (PHASE1, PHASE2)
- A Study of Olomorasib (LY3537982) in Healthy Participants (PHASE1)
- The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study (NA)
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. (PHASE3)
- A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (PHASE1, PHASE2)
- Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial (PHASE3)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluconazol CI brief — competitive landscape report
- Fluconazol updates RSS · CI watch RSS
- Azienda Sanitaria-Universitaria Integrata di Udine portfolio CI